Last updated on November 2019

Iclusig (Ponatinib) in Clinical Practice for the Treatment of Chronic Myeloid Leukemia or Ph+ Acute Lymphoblastic Leukemia in Belgium

Brief description of study

This prospective registry is initiated to follow up on the use of Iclusig in patients with CML or Ph+ ALL in routine practice in Belgium.

Clinical Study Identifier: NCT03678454

Find a site near you

Start Over

AZ Turnhout St-Elisabeth

Turnhout, Belgium
  Connect »